Sex selection bias in schizophrenia antipsychotic trials.

Abstract:

:The sex prevalence of schizophrenia is approximately equal, and yet clinical trials of new therapeutic drugs have been conducted, for the most part, with male participants. The authors reviewed the percentage of women in schizophrenia clinical trials of the new "atypical" antipsychotic medications. MEDLINE and Cochrane databases were searched for English-language randomized controlled trials involving risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Studies with a sample size of more than 50 and a subject diagnosis of schizophrenia, schizophrenia spectrum disorder, or broad psychosis were included for review. For each study, the following items were abstracted: source of support, pharmacotherapy, site location, treatment setting, patient phase, psychotic episode number, duration, number of men and women in the total sample, mean age of the sample, and the presence of women-specific inclusion/exclusion criteria. Sixty-seven published studies met criteria. The median percentage of women in the total sample was 33.3%, the minimum was 6.7%, and the maximum was 71.2%. A stepwise linear regression analysis showed that age (younger samples), center location (Unites States and Canada), treatment patient setting (inpatient), and ziprasidone trials were all associated with relatively lower percentages of women. Sex differences in antipsychotic pharmacokinetics and pharmacodynamics that may result in differential effectiveness and susceptibility to adverse effects cannot be ascertained when the percentage of women in clinical trials is as low as it is. The increasing shift toward outpatient rather than inpatient drug trials may help to increase the proportion of women.

journal_name

J Clin Psychopharmacol

authors

Chaves AC,Seeman MV

doi

10.1097/01.jcp.0000236652.78168.ee

subject

Has Abstract

pub_date

2006-10-01 00:00:00

pages

489-94

issue

5

eissn

0271-0749

issn

1533-712X

pii

00004714-200610000-00009

journal_volume

26

pub_type

杂志文章,meta分析
  • Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.

    abstract::The aim of this study was to estimate the long-term effectiveness of olanzapine as adjunctive therapy in patients with bipolar disorder who exhibited an inadequate response to mood stabilizers. Twenty-three Research Diagnostic Criteria (RDC) patients with bipolar I and II were assessed by means of the Schedule for Aff...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200110000-00002

    authors: Vieta E,Reinares M,Corbella B,Benabarre A,Gilaberte I,Colom F,Martínez-Arán A,Gastó C,Tohen M

    更新日期:2001-10-01 00:00:00

  • Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

    abstract::Twenty-four healthy male and female subjects, who participated in this randomized, double-blind, crossover study, received single nighttime doses of zaleplon 10 mg (therapeutic dose), zaleplon 20 mg, zolpidem 10 mg (therapeutic dose), zolpidem 20 mg, triazolam 0.25 mg (positive control), and placebo. Subjective behavi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200006000-00007

    authors: Troy SM,Lucki I,Unruh MA,Cevallos WH,Leister CA,Martin PT,Furlan PM,Mangano R

    更新日期:2000-06-01 00:00:00

  • Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.

    abstract:OBJECTIVE:Efficacy of atypical antipsychotic in acute schizophrenic episodes is still in debate. This study evaluated treatment practices over 7 years of initial treatment with oral risperidone in acutely exacerbated patients with schizophrenia and in a subgroup of highly agitated, tense, and aggressive patients. Addit...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/01.jcp.0000170686.27476.ab

    authors: Pajonk FG,Schreiner A,Peters S,Rettig K,Degner D,Rüther E

    更新日期:2005-08-01 00:00:00

  • Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.

    abstract::The pharmacokinetics of drugs with specific binding sites in the brain needs to be evaluated at these sites. In this study, we measured the time course of the selective serotonin reuptake inhibitor fluvoxamine in the human brain based on serotonin transporter (5-HTT) occupancy by positron emission tomography. Consecut...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000203201.34323.d3

    authors: Takano A,Suhara T,Ichimiya T,Yasuno F,Suzuki K

    更新日期:2006-04-01 00:00:00

  • Assessment of Drug-Associated Extrapyramidal Symptoms in People With Intellectual Disability: A Comparison of an Informant-Based Scale With Clinical Rating Scales.

    abstract::Drug-associated extrapyramidal symptoms (EPS) in people with intellectual disability (ID) may be difficult to recognize, and clinicians' assessments may be hampered by lack of patients' capacities to adequately cooperate and by lack of reliable instruments to measure EPS in this population. Therefore, we compared asse...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000558

    authors: de Kuijper GM,Hoekstra PJ

    更新日期:2016-10-01 00:00:00

  • Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

    abstract:PURPOSE:This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS:Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000674

    authors: Mosca D,Zhang M,Prieto R,Boucher M

    更新日期:2017-04-01 00:00:00

  • Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens.

    abstract::Effects of venlafaxine, an antidepressant acting by selective serotonin and norepinephrine reuptake inhibition with a potency ratio of 5:1, were assessed in a standardized, actual driving test, a battery of psychomotor tests (Critical Flicker/Fusion Frequency, Critical Tracking, Divided Attention), and a 45-minute vig...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199806000-00006

    authors: O'Hanlon JF,Robbe HW,Vermeeren A,van Leeuwen C,Danjou PE

    更新日期:1998-06-01 00:00:00

  • Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.

    abstract::The measurement of plasma clozapine concentrations is useful in assessing compliance, optimizing therapy, and minimizing toxicity. We measured plasma clozapine and norclozapine (N-desmethylclozapine) concentrations in samples from 3782 patients (2648 male, 1127 female). No clozapine was detected in 291 samples (227 pa...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000106221.36344.4d

    authors: Rostami-Hodjegan A,Amin AM,Spencer EP,Lennard MS,Tucker GT,Flanagan RJ

    更新日期:2004-02-01 00:00:00

  • Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.

    abstract::The Taq1A polymorphism in the dopamine D2 receptor (DRD2) gene could be related to the response to antipsychotics. We examined the effects of the Taq1A polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a DRD2 partial agonist. Thirty Japanese patients with schizop...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e31823f87ac

    authors: Miura I,Takeuchi S,Katsumi A,Mori A,Kanno K,Yang Q,Mashiko H,Numata Y,Niwa S

    更新日期:2012-02-01 00:00:00

  • Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers.

    abstract::The neurotransmitter dopamine is integrally involved in the rewarding effects of drugs, and it has also been thought to mediate impulsive behaviors in animal models. Most of the studies of drug effects on impulsive behaviors in humans have involved drugs with complex actions on different transmitter systems and differ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/jcp.0b013e3181602fab

    authors: Hamidovic A,Kang UJ,de Wit H

    更新日期:2008-02-01 00:00:00

  • α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.

    abstract:PURPOSE:The aim of this article is to review the recent trials of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists and positive allosteric modulators (PAMs) on the treatment of cognitive decline in schizophrenia. α7 Nicotinic acetylcholine receptor abnormalities in schizophrenia and clinical implications of α7 n...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0000000000000859

    authors: Jones C

    更新日期:2018-06-01 00:00:00

  • WITHDRAWN:A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome.

    abstract::Ahead of Print article withdrawn by publisher. ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31829ab413

    authors: Gurrera RJ,Velamoor V,Cernovsky ZZ

    更新日期:2013-08-22 00:00:00

  • A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response.

    abstract::Although a relatively common behavior, treatment data for pathological skin picking (PSP) are limited. The current study sought to examine the efficacy and tolerability of lamotrigine in adults with PSP and to examine neurocognitive predictors of treatment response. Thirty-two subjects (29 female subjects [90.6%]; mea...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e3181e617a1

    authors: Grant JE,Odlaug BL,Chamberlain SR,Kim SW

    更新日期:2010-08-01 00:00:00

  • Pharmacokinetics of valproate and carbamazepine.

    abstract::Over the past 10 years, knowledge gained about the pharmacokinetic profiles of valproate and carbamazepine has increased the clinical effectiveness of their use. Much of the information has been gained through their use as successful antiepileptic medications. As these agents begin to play an increasing role as mood-s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199202001-00010

    authors: Wilder BJ

    更新日期:1992-02-01 00:00:00

  • Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.

    abstract::This investigation aimed to provide evidence on the lack of pharmacokinetic interaction of paroxetine (20 mg/d) and alprazolam (1 mg/d) in combined therapy. In addition, the central effects of both drugs when administered alone and in combination were assessed to rule out any relevant synergistic depressant central ef...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000125689.05091.c6

    authors: Calvo G,García-Gea C,Luque A,Morte A,Dal-Ré R,Barbanoj M

    更新日期:2004-06-01 00:00:00

  • A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder.

    abstract::This UK multicenter, noncomparative, open-trial study assessed risperidone in 74 first-psychotic-episode patients (DSM-IV schizophrenia) treated with flexible doses. Treatment commenced at 1 mg/day, increasing to 2 mg after 3 days; then adjusted to 8 mg/day maximum. Treatment duration was 12 weeks (Phase 1) with follo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/01.jcp.0000115663.45074.8a

    authors: Huq ZU,RIS-GBR-32 Investigators.

    更新日期:2004-04-01 00:00:00

  • Longitudinally Measured Changes in Somnolence Severity With a Visual Analog Scale in a Randomized Lithium Versus Quetiapine-IR Study in Bipolar Disorder.

    abstract:OBJECTIVE:The aim of this study was to use a visual analog scale (VAS) longitudinally measuring somnolence severity in patients with bipolar disorder. METHODS:A data set of patients with bipolar spectrum disorders who were randomized to lithium or quetiapine-IR for 16 weeks was used. The somnolence severity was measur...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000001031

    authors: Gao K,Su M,Ganocy SJ,Goto T,Yuan C,Fang F,Conroy C,Brownrigg B,Serrano MB,Calabrese JR

    更新日期:2019-05-01 00:00:00

  • Specific side effects of long-term imipramine management of panic disorder.

    abstract::In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2.25 mg/kg/day. Although sexual dysfunction and weight...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200204000-00008

    authors: Mavissakalian M,Perel J,Guo S

    更新日期:2002-04-01 00:00:00

  • Teaching psychopharmacology: what works and what doesn't.

    abstract::How do we best teach clinical psychopharmacology to trainees and clinicians, so they not only increase their knowledge base, but even more importantly also learn to practice the most informed, evidence-based practice possible? This article attempts to answer this elusive question by compiling the individual and combin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/jcp.0b013e3181603f6b

    authors: Zisook S,Glick ID,Jefferson JW,Wagner KD,Salzman C,Peselow ED,Stahl S

    更新日期:2008-02-01 00:00:00

  • Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

    abstract::This paper examines the relationship between plasma concentration of antidepressant and both clinical response and adverse effects in treatment-resistant depressed adolescents. Adolescents (n = 334) with major depression who had not responded to a selective serotonin reuptake inhibitor (SSRI) were randomized to 1 of 4...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e318204b117

    authors: Sakolsky DJ,Perel JM,Emslie GJ,Clarke GN,Wagner KD,Vitiello B,Keller MB,Birmaher B,Asarnow JR,Ryan ND,McCracken JT,Strober MJ,Iyengar S,Porta G,Brent DA

    更新日期:2011-02-01 00:00:00

  • The effect of chronic alprazolam on sleep and bioamine metabolites in depression.

    abstract::Alprazolam administered for 43 days in doses of 6 to 10 mg/day had an antidepressant effect in four of nine depressed patients. Decreases in slow wave sleep, increases in rapid eye movement (REM) latency, and decreases in REM minutes and percent and REM sleep eye movements were found in the group as a whole. The drug ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Zarcone VP Jr,Benson KL,Greene KA,Csernansky JG,Faull KF

    更新日期:1994-02-01 00:00:00

  • Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review.

    abstract::Adult attention deficit/hyperactivity disorder (ADHD) is an increasingly recognized disorder with associated psychiatric comorbidity and impairment. Although pharmacotherapy serves an important role in treating ADHD and other concurrent psychiatric disorders in children and adolescents, the use of pharmacotherapeutics...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199508000-00006

    authors: Wilens TE,Biederman J,Spencer TJ,Prince J

    更新日期:1995-08-01 00:00:00

  • Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.

    abstract::We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year. Blood samples were obtained after an 11-hour (+/...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000227705.56870.06

    authors: Hardy TA,Marquez E,Kryzhanovskaya L,Taylor CC,Cavazzoni P

    更新日期:2006-08-01 00:00:00

  • Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.

    abstract::This 12-week, double-blind, multicenter trial evaluated the efficacy of venlafaxine extended release (ER), sertraline, and placebo in adult outpatients (N = 538) with a primary diagnosis of posttraumatic stress disorder (PTSD), as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, sy...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.jcp.0000222514.71390.c1

    authors: Davidson J,Rothbaum BO,Tucker P,Asnis G,Benattia I,Musgnung JJ

    更新日期:2006-06-01 00:00:00

  • The side effects burden of extended imipramine treatment of panic disorder.

    abstract::In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2.25 mg x kg(-1) x day(-1), 59 adhered to the regimen and showed a marked and stable resp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200010000-00010

    authors: Mavissakalian MR,Perel JM

    更新日期:2000-10-01 00:00:00

  • The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder.

    abstract::The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 m...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e31802e5115

    authors: Davidson JR,Brady K,Mellman TA,Stein MB,Pollack MH

    更新日期:2007-02-01 00:00:00

  • Interrater reliability of the modified Monitoring of Side Effects Scale for assessment of adverse effects of psychiatric medication in clinical and research settings.

    abstract::The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000311

    authors: Nugent KL,Spahr E,Toroney J,Mojtabai R,Nettles C,Turner LW,Fenton A,Spivak A,Cullen BA,Everett A,Eaton WW

    更新日期:2015-06-01 00:00:00

  • The young adult chronic patient: population overview.

    abstract::Uninstitutionalized young adults with chronic mental disorders and social disabilities pose a new challenge in community psychiatry. These attention-seeking, help-rejecting young men and women spend most of their lives in the community and differ markedly from older deinstitutionalized chronic psychiatric patients. Ma...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Pepper B

    更新日期:1985-06-01 00:00:00

  • Comorbidity of anxiety and depression.

    abstract::Many factors obscure the diagnosis of psychogenic disorders, especially anxiety and depression. The factors involved include an overlap of symptoms, discrepancies in diagnostic criteria, and the unreliability of self- and observer-reporting. Differentiation among the various personality disorders is, however, extremel...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199006001-00009

    authors: Cloninger CR

    更新日期:1990-06-01 00:00:00

  • The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression.

    abstract:BACKGROUND:Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical exp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000636

    authors: Kelly T,Lieberman DZ

    更新日期:2017-02-01 00:00:00